Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
Monash Heart, Monash Health, Melbourne, VIC, Australia.
J Hum Hypertens. 2023 Nov;37(11):1043-1046. doi: 10.1038/s41371-023-00831-z. Epub 2023 Apr 19.
Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.
免疫检查点抑制剂（ICI）是一种癌症治疗药物，与动脉粥样硬化性心血管疾病（ASCVD）风险增加有关。在进行 ICI 治疗的日间肿瘤中心就诊期间，通常会常规测量血压（BP），但通常不会进行时间评估以筛查和监测高血压，而高血压可能会独立增加癌症幸存者 ASCVD 的风险。本研究报告了使用来自日间肿瘤中心常规就诊的连续 BP 测量值来诊断和监测接受 ICI 的癌症患者的高血压控制情况的可行性。
